Popular Articles
Grapefruit Benefits

Leicester Geneticists Unearth The Roots Of Human Genetic Variation
A new study at the University of Leicester is using advanced single molecule methods to explore processes that lie at the very core of DNA variation in humans.
generic viagra online
Cardium Presents Gene Activated Matrix Technology And Update On Excellarate Clinical Development Program At ASGT Annual Meeting
Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) announced a presentation entitled "Phase 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment of Diabetic Ulcers" at the Late Stage Industry Clinical Trials Symposium at the American Society of Gene Therapy (ASGT) Annual meeting in San Diego, California, on May 27, 2009. Dr. Barbara K. Sosnowski, Cardium"s Vice President of Biologics Development and the Chief Operating Officer of Cardium"s Tissue Repair Company Operating Unit, provided an update on TRC"s Phase 2b MATRIX clinical trial and the new formulation of the Excellarate(TM) product candidate, as well as an overview of the prior clinical study of Excellarate.
News of the day
Nonin Medical Announces FDA Clearance For Its Next-Generation Regional Oximetry System
Nonin Medical, Inc., a leading innovator of noninvasive physiological monitoring solutions, announced FDA clearance for its Model 7600 Regional Oximetry System. Introduced in June 2009 at the European Society of Anaesthesiology (ESA) conference in Milan, Italy, the innovative Model 7600 offers real-time monitoring of cerebral oxygenation for patients at risk of ischemia.
Medical Devices

American Psychiatric Association Endorses Commitment To Closing The Medicare "Doughnut Hole"

The American Psychiatric Association (APA) commended the Senate Finance Committee, the Obama administration and the nation"s pharmaceutical companies today for addressing the Medicare coverage gap in prescription drug plans for America"s seniors. The coverage gap, known as the Medicare "doughnut hole," excludes coverage for the annual costs of prescription medications that exceed $2,700 but don"t reach $6,154, a gap that APA president Alan Schatzberg called "an excessive burden to those over 65 and those who are chronically disabled, including those suffering from mental illnesses." Under the new agreement on the part of Congress and PhRMA, the largest organization representing the pharmaceutical industry, drug companies will provide $80 billion to cover up to 50 percent of the cost of brand-name medications that fall through the gap in Medicare"s Part D prescription program. The agreement is being discussed as part of the major health care reform legislation being considered by Congress. "Although this is a first step, it is a step in the direction of providing high-quality, affordable health care to all Americans," Dr. Schatzberg said. "The APA recognizes that full prescription coverage is an integral part of any meaningful health care reform and applauds the effort to eliminate one of the most glaring deficiencies in Medicare." "We hope to see this agreement take effect as part of a package that includes the comprehensive and universal health care coverage that the American people need and deserve," Dr. Schatzberg said. American Psychiatric Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):